Fleming S J, Foreman K, Shanley K, Mihrshahi R, Siskind V
Department of Renal Medicine, Royal Brisbane Hospital, Herston, Australia.
Am J Nephrol. 1991;11(1):27-31. doi: 10.1159/000168268.
We evaluated the dialyser reprocessing agent Renalin in a 6-month prospective study of 2,759 dialyses on 59 patients. Dialysers were withdrawn after a maximum of 6 uses, and the average number of uses achieved was 4.5 Dialyser survival varied with the type of dialyser but was unaffected by the dialysate base. In vivo clearances of urea, creatinine and phosphate were not altered by reuse, but there was a small decrease in ultrafiltration characteristics of used dialysers. No clinically significant adverse event was attributed to reuse. Blood pressure was better preserved with used dialysers, and patients experienced significantly fewer intradialytic symptoms. Savings of over +A 25,000 were achieved during the study.
我们在一项针对59例患者进行的2759次透析的为期6个月的前瞻性研究中，对透析器再处理剂Renalin进行了评估。透析器最多使用6次后停用，平均使用次数为4.5次。透析器的使用寿命因透析器类型而异，但不受透析液碱基的影响。尿素、肌酐和磷酸盐的体内清除率不会因复用而改变，但复用后的透析器超滤性能略有下降。没有临床显著的不良事件归因于复用。使用复用透析器时血压能更好地维持，患者透析期间出现的症状也明显更少。在研究期间节省了超过25,000澳元。
